Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Optom Vis Sci ; 99(8): 626-631, 2022 08 01.
Article in English | MEDLINE | ID: mdl-35848984

ABSTRACT

SIGNIFICANCE: The real-world pharmacological use of netarsudil shows that it can produce a clinically significant decrease in intraocular pressure for a small group of patients, even if they are already taking three or four other hypotensive glaucoma medication classes. PURPOSE: This study aimed to assess the effectiveness of netarsudil in reducing intraocular pressure among veterans with advanced glaucoma on maximally tolerated medical therapy. METHODS: All patients with glaucoma who received netarsudil between June 2018 and April 2020 from the West Los Angeles Veterans Administration Medical Center were reviewed. Inclusion criteria included a minimum of one intraocular pressure measurement in each of two time windows (within and after 4 months of netarsudil use). Exclusion criteria included medication nonadherence, change in treatment plan before post-treatment intraocular pressure could be obtained, corneal disease precluding reliable measurement, outside follow-up, and loss to follow-up. Intraocular pressure at baseline and that at two time windows were compared using analyses of variance. Relationships between intraocular pressure and number of baseline medications and concurrent statin therapy were evaluated. Netarsudil tolerability was reported. RESULTS: Of 200 patients prescribed netarsudil, 42 patients (eyes) met the enrollment criteria. The mean age of these patients was 75.7 years (95% confidence interval [CI], 73.0 to 78.4 years), 64% were of African descent, 79% had open-angle glaucoma, and the mean number of baseline medications was 3.7 (95% CI, 3.5 to 3.9). Baseline intraocular pressure of 17.2 mmHg (95% CI, 16.1 to 18.2 mmHg) decreased to 15.1 mmHg (95% CI, 14.0 to 16.2 mmHg; P < .001), and a reduction of >20% was seen in 30.9% of patient after 4 months of netarsudil therapy. Intraocular pressure reduction was not associated with number of baseline medications or systemic statin use. CONCLUSIONS: Netarsudil may produce a clinically significant intraocular pressure reduction in up to a third of the patients with advanced glaucoma already on maximally tolerated medical therapy.


Subject(s)
Glaucoma, Open-Angle , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Ocular Hypertension , Veterans , Aged , Antihypertensive Agents , Glaucoma, Open-Angle/drug therapy , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Intraocular Pressure , Ocular Hypertension/drug therapy , rho-Associated Kinases/therapeutic use
2.
Autism Res ; 13(10): 1685-1697, 2020 10.
Article in English | MEDLINE | ID: mdl-32815320

ABSTRACT

Mutations in CHD8 are among the most common autism-causing genetic defects identified in human genomics studies. Therefore, many labs have attempted to model this disorder by generating mice with mutations in Chd8. Using a gene trap inserted after Exon 31, we created a novel Chd8 mutant mouse (Chd8+/E31T ) and characterized its behavior on several different assays thought to have face validity for the human condition, attempting to model both the core symptoms (repetitive behaviors and social communication impairments) and common comorbidities (motor deficits, anxiety, and intellectual disability). We found that Chd8+/E31T mice showed no difference compared to wild-type mice in amount of self-grooming, reproducing the negative finding most other studies have reported. Unlike some of the other published lines, Chd8+/E31T mice did not show deficits in the three-chamber test for social novelty preference. A few studies have examined ultrasonic vocalizations in Chd8 mutant mice, but we are the first to report an increase in call length for adult mice. Additionally, we found that in contrast to previous published lines, Chd8+/E31T mice displayed no anxiety-like behaviors or learning impairments but showed paradoxically significant improvement in motor function. The inconsistencies in behavioral phenotypes in the Chd8 mutant mice generated by different laboratories poses a challenge for modeling autism spectrum disorder and preclinical studies in mice going forward and warrants further investigation into the molecular consequences of the different mutations in Chd8 and the functional impact on behavior. LAY SUMMARY: Several different mouse models carrying mutations in the Chd8 gene have been created to study the effects of these autism-causing mutations in the laboratory. The current study characterizes a novel Chd8 mutant mouse model as well as summarizes data from previously published Chd8 mutant mice. The inconsistencies between different studies are concerning, but future research into the reasons why these inconsistencies occur may help us understand why patients with various mutations have different degrees of symptom severity. Autism Res 2020, 13: 1685-1697. © 2020 International Society for Autism Research and Wiley Periodicals LLC.


Subject(s)
Autistic Disorder , Social Communication Disorder , Animals , Autistic Disorder/genetics , DNA-Binding Proteins , Disease Models, Animal , Female , Male , Mice , Transcription Factors , Ultrasonics , Vocalization, Animal
3.
Mol Autism ; 9: 65, 2018.
Article in English | MEDLINE | ID: mdl-30574290

ABSTRACT

Background: Mutations in CHD8, chromodomain helicase DNA-binding protein 8, are among the most replicated and common findings in genetic studies of autism spectrum disorder (ASD). The CHD8 protein is believed to act as a transcriptional regulator by remodeling chromatin structure and recruiting histone H1 to target genes. The mechanism by which deficiency of CHD8 causes ASD has not been fully elucidated. Methods: We examined the expression of CHD8 in human and mouse brains using both immunohistochemistry and RNA in situ hybridization. We performed in utero electroporation, neuronal culture, and biochemical analysis using RNAi to examine the functional consequences of CHD8 deficiency. Results: We discovered that CHD8 is expressed highly in neurons and at low levels in glia cells in both humans and mice. Specifically, CHD8 is localized predominately in the nucleus of both MAP2 and parvalbumin-positive neurons. In the developing mouse brain, expression of Chd8 peaks from E16 to E18 and then decreases significantly at P14 to adulthood. Knockdown of Chd8 results in reduced axon and dendritic growth, disruption of axon projections to the contralateral cortex, and delayed neuronal migration at E18.5 which recovers by P3 and P7. Conclusion: Our findings indicate an important role for CHD8 in dendritic and axon development and neuronal migration and thus offer novel insights to further dissect the underlying molecular and circuit mechanisms of ASD caused by CHD8 deficiency.


Subject(s)
Autistic Disorder/genetics , DNA-Binding Proteins/genetics , Neurogenesis , Neurons/metabolism , Animals , Autistic Disorder/pathology , Cells, Cultured , Cerebral Cortex/cytology , Cerebral Cortex/growth & development , DNA-Binding Proteins/metabolism , Humans , Mice , Mice, Inbred C57BL , Neurons/cytology , Neurons/physiology
4.
Brain Behav ; 8(11): e01107, 2018 11.
Article in English | MEDLINE | ID: mdl-30317697

ABSTRACT

INTRODUCTION: Several studies have supported the use of enriched environments to prevent the manifestation of ASD-like phenotypes in laboratory rodents. While the translational value of such experiments is unknown, the findings have been relatively consistent across many different models. METHODS: In the current study, we tested the effects of early environmental enrichment on a mouse model of ASD with high construct validity, the Shank3 ∆e4-22 mice our laboratory previously generated and characterized. RESULTS: Contrary to previous reports, we found no benefits of enriched rearing, including no change in repetitive self-grooming or hole-board exploration. Instead, we found that early environmental enrichment increased anxiety-like behavior in all mice regardless of genotype and decreased motor performance specifically in wild-type mice. CONCLUSIONS: Although using a different enrichment protocol may have rescued the phenotypes in our mouse model, these results suggest that a "one-size fits all" approach may not be the best when it comes to behavioral intervention for ASD and underscores the need for effective pharmaceutical development in certain genetic syndromes with severe symptom presentation.


Subject(s)
Autism Spectrum Disorder/psychology , Environment , Animal Husbandry/methods , Animals , Anxiety/etiology , Disease Models, Animal , Exploratory Behavior/physiology , Female , Genotype , Grooming/physiology , Male , Mice, Inbred C57BL , Mice, Knockout , Microfilament Proteins , Nerve Tissue Proteins/deficiency , Phenotype
5.
Transl Psychiatry ; 8(1): 94, 2018 04 27.
Article in English | MEDLINE | ID: mdl-29700290

ABSTRACT

We previously reported a new line of Shank3 mutant mice which led to a complete loss of Shank3 by deleting exons 4-22 (Δe4-22) globally. Δe4-22 mice display robust ASD-like behaviors including impaired social interaction and communication, increased stereotypical behavior and excessive grooming, and a profound deficit in instrumental learning. However, the anatomical and neural circuitry underlying these behaviors are unknown. We generated mice with Shank3 selectively deleted in forebrain, striatum, and striatal D1 and D2 cells. These mice were used to interrogate the circuit/brain-region and cell-type specific role of Shank3 in the expression of autism-related behaviors. Whole-cell patch recording and biochemical analyses were used to study the synaptic function and molecular changes in specific brain regions. We found perseverative exploratory behaviors in mice with deletion of Shank3 in striatal inhibitory neurons. Conversely, self-grooming induced lesions were observed in mice with deletion of Shank3 in excitatory neurons of forebrain. However, social, communicative, and instrumental learning behaviors were largely unaffected in these mice, unlike what is seen in global Δe4-22 mice. We discovered unique patterns of change for the biochemical and electrophysiological findings in respective brain regions that reflect the complex nature of transcriptional regulation of Shank3. Reductions in Homer1b/c and membrane hyper-excitability were observed in striatal loss of Shank3. By comparison, Shank3 deletion in hippocampal neurons resulted in increased NMDAR-currents and GluN2B-containing NMDARs. These results together suggest that Shank3 may differentially regulate neural circuits that control behavior. Our study supports a dissociation of Shank3 functions in cortical and striatal neurons in ASD-related behaviors, and it illustrates the complexity of neural circuit mechanisms underlying these behaviors.


Subject(s)
Autism Spectrum Disorder/physiopathology , Autism Spectrum Disorder/psychology , Corpus Striatum/physiopathology , Nerve Tissue Proteins/physiology , Prosencephalon/physiopathology , Animals , Behavior, Animal , Corpus Striatum/metabolism , Disease Models, Animal , Excitatory Postsynaptic Potentials , Hippocampus/metabolism , Hippocampus/physiopathology , Homer Scaffolding Proteins/metabolism , Mice, Knockout , Microfilament Proteins , Nerve Tissue Proteins/genetics , Neurons/physiology , Phenotype , Prosencephalon/metabolism , Receptors, Dopamine D1/physiology , Receptors, Dopamine D2/physiology , Receptors, N-Methyl-D-Aspartate/physiology , Social Behavior , Synapses/metabolism
6.
Elife ; 72018 04 03.
Article in English | MEDLINE | ID: mdl-29611808

ABSTRACT

A common strategy by which developing neurons locate their synaptic partners is through projections to circuit-specific neuropil sublayers. Once established, sublayers serve as a substrate for selective synapse formation, but how sublayers arise during neurodevelopment remains unknown. Here, we identify the earliest events that initiate formation of the direction-selective circuit in the inner plexiform layer of mouse retina. We demonstrate that radially migrating newborn starburst amacrine cells establish homotypic contacts on arrival at the inner retina. These contacts, mediated by the cell-surface protein MEGF10, trigger neuropil innervation resulting in generation of two sublayers comprising starburst-cell dendrites. This dendritic scaffold then recruits projections from circuit partners. Abolishing MEGF10-mediated contacts profoundly delays and ultimately disrupts sublayer formation, leading to broader direction tuning and weaker direction-selectivity in retinal ganglion cells. Our findings reveal a mechanism by which differentiating neurons transition from migratory to mature morphology, and highlight this mechanism's importance in forming circuit-specific sublayers.


Subject(s)
Amacrine Cells/physiology , Neuropil/physiology , Retina/embryology , Retinal Ganglion Cells/physiology , Animals , Membrane Proteins/metabolism , Mice
7.
Neurosci Bull ; 33(2): 205-218, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28271437

ABSTRACT

Transgenic mice carrying mutations that cause Autism Spectrum Disorders (ASDs) continue to be valuable for determining the molecular underpinnings of the disorders. Recently, researchers have taken advantage of such models combined with Cre-loxP and similar systems to manipulate gene expression over space and time. Thus, a clearer picture is starting to emerge of the cell types, circuits, brain regions, and developmental time periods underlying ASDs. ASD-causing mutations have been restricted to or rescued specifically in excitatory or inhibitory neurons, different neurotransmitter systems, and cells specific to the forebrain or cerebellum. In addition, mutations have been induced or corrected in adult mice, providing some evidence for the plasticity and reversibility of core ASD symptoms. The limited availability of Cre lines that are highly specific to certain cell types or time periods provides a challenge to determining the cellular and circuitry bases of autism, but other technological advances may eventually overcome this obstacle.


Subject(s)
Autistic Disorder , Brain/pathology , Gene Expression , Genetic Techniques , Transgenes/genetics , Animals , Autistic Disorder/complications , Autistic Disorder/genetics , Autistic Disorder/pathology , Humans , Mice , Mice, Transgenic , Mutation , Neurons/pathology , Social Communication Disorder/etiology
8.
Nat Med ; 23(2): 213-222, 2017 Feb.
Article in English | MEDLINE | ID: mdl-28024084

ABSTRACT

Prader-Willi syndrome (PWS) is an imprinting disorder caused by a deficiency of paternally expressed gene(s) in the 15q11-q13 chromosomal region. The regulation of imprinted gene expression in this region is coordinated by an imprinting center (PWS-IC). In individuals with PWS, genes responsible for PWS on the maternal chromosome are present, but repressed epigenetically, which provides an opportunity for the use of epigenetic therapy to restore expression from the maternal copies of PWS-associated genes. Through a high-content screen (HCS) of >9,000 small molecules, we discovered that UNC0638 and UNC0642-two selective inhibitors of euchromatic histone lysine N-methyltransferase-2 (EHMT2, also known as G9a)-activated the maternal (m) copy of candidate genes underlying PWS, including the SnoRNA cluster SNORD116, in cells from humans with PWS and also from a mouse model of PWS carrying a paternal (p) deletion from small nuclear ribonucleoprotein N (Snrpn (S)) to ubiquitin protein ligase E3A (Ube3a (U)) (mouse model referred to hereafter as m+/pΔS-U). Both UNC0642 and UNC0638 caused a selective reduction of the dimethylation of histone H3 lysine 9 (H3K9me2) at PWS-IC, without changing DNA methylation, when analyzed by bisulfite genomic sequencing. This indicates that histone modification is essential for the imprinting of candidate genes underlying PWS. UNC0642 displayed therapeutic effects in the PWS mouse model by improving the survival and the growth of m+/pΔS-U newborn pups. This study provides the first proof of principle for an epigenetics-based therapy for PWS.


Subject(s)
Enzyme Inhibitors/pharmacology , Gene Expression/drug effects , Histone Code/drug effects , Histone-Lysine N-Methyltransferase/antagonists & inhibitors , Prader-Willi Syndrome/genetics , Quinazolines/pharmacology , RNA, Small Nucleolar/drug effects , Animals , Blotting, Western , Cell Line , Disease Models, Animal , Epigenesis, Genetic , Female , Fibroblasts/drug effects , Fibroblasts/metabolism , Gene Expression/genetics , Genomic Imprinting , Histone Code/genetics , Humans , Immunohistochemistry , Male , Methylation/drug effects , Mice , Prader-Willi Syndrome/metabolism , RNA, Small Nucleolar/genetics , Reverse Transcriptase Polymerase Chain Reaction , Survival Rate , Ubiquitin-Protein Ligases/genetics , snRNP Core Proteins/genetics
9.
Nat Commun ; 7: 11459, 2016 05 10.
Article in English | MEDLINE | ID: mdl-27161151

ABSTRACT

Human neuroimaging studies suggest that aberrant neural connectivity underlies behavioural deficits in autism spectrum disorders (ASDs), but the molecular and neural circuit mechanisms underlying ASDs remain elusive. Here, we describe a complete knockout mouse model of the autism-associated Shank3 gene, with a deletion of exons 4-22 (Δe4-22). Both mGluR5-Homer scaffolds and mGluR5-mediated signalling are selectively altered in striatal neurons. These changes are associated with perturbed function at striatal synapses, abnormal brain morphology, aberrant structural connectivity and ASD-like behaviour. In vivo recording reveals that the cortico-striatal-thalamic circuit is tonically hyperactive in mutants, but becomes hypoactive during social behaviour. Manipulation of mGluR5 activity attenuates excessive grooming and instrumental learning differentially, and rescues impaired striatal synaptic plasticity in Δe4-22(-/-) mice. These findings show that deficiency of Shank3 can impair mGluR5-Homer scaffolding, resulting in cortico-striatal circuit abnormalities that underlie deficits in learning and ASD-like behaviours. These data suggest causal links between genetic, molecular, and circuit mechanisms underlying the pathophysiology of ASDs.


Subject(s)
Autism Spectrum Disorder/physiopathology , Cerebral Cortex/physiopathology , Corpus Striatum/physiopathology , Homer Scaffolding Proteins/metabolism , Nerve Tissue Proteins/deficiency , Receptor, Metabotropic Glutamate 5/metabolism , Animals , Autism Spectrum Disorder/genetics , Autism Spectrum Disorder/pathology , Behavior, Animal , Cerebral Cortex/pathology , Corpus Striatum/pathology , Female , Humans , Long-Term Synaptic Depression , Male , Mice , Mice, Knockout , Microfilament Proteins , Models, Neurological , Nerve Net/pathology , Nerve Net/physiopathology , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/physiology , Sequence Deletion , Social Behavior
SELECTION OF CITATIONS
SEARCH DETAIL
...